Heron Therapeuti (HRTX)vsRoyalty Pharma Plc (RPRX)
HRTX
Heron Therapeuti
$0.32
-4.96%
HEALTHCARE · Cap: $92.90M
RPRX
Royalty Pharma Plc
$59.45
+1.45%
HEALTHCARE · Cap: $33.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 1583% more annual revenue ($2.54B vs $150.71M). RPRX leads profitability with a 32.0% profit margin vs -20.5%. RPRX earns a higher WallStSmart Score of 53/100 (C-).
HRTX
Avoid27
out of 100
Grade: F
RPRX
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HRTX.
Margin of Safety
-60.9%
Fair Value
$36.41
Current Price
$59.45
$23.04 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Generating 1.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -338.6% — below average capital efficiency
Revenue declined 10.8%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 46.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : HRTX
HRTX has a balanced fundamental profile.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth, Free Cash Flow. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : HRTX
The primary concerns for HRTX are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 21.48 is elevated, increasing financial risk.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
HRTX profiles as a turnaround stock while RPRX is a growth play — different risk/reward profiles.
HRTX carries more volatility with a beta of 1.67 — expect wider price swings.
RPRX is growing revenue faster at 16.5% — sustainability is the question.
RPRX generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (53/100 vs 27/100), backed by strong 32.0% margins and 16.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Heron Therapeuti
HEALTHCARE · BIOTECHNOLOGY · USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?